Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abemaciclib - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Abemaciclib - Eli Lilly and Company

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; Verzenios

Latest Information Update: 01 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III HER2 negative breast cancer; Liposarcoma; Prostate cancer
  • Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
  • Phase I/II Head and neck cancer
  • Phase I Myelofibrosis
  • No development reported Cancer; Renal cell carcinoma

Most Recent Events

  • 27 Jun 2024 phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease) is ongoing in Finland, Denmark (PO, Tablet) (NCT03099174)
  • 27 Jun 2024 Phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) is ongoing in Spain, Japan, France, Finland, Denmark, USA, (PO) (NCT03099174)
  • 26 Jun 2024 Eli Lilly and Company terminates a phase-III clinical trials in Breast cancer (Combination therapy, Early-stage disease, Second-line therapy or greater) in Mexico, Israel, Hungary, Greece, France, China, Brazil, Austria, Argentina, USA, Australia, Japan, South Korea, Taiwan, USA, Austria, Japan, Germany, Italy, Spain, Switzerland and United Kingdom (PO) due to inability to enroll study participants (NCT04752332)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top